Vistagen Therapeutics, Inc.: Form 10-Q for the period ended Dec 31, 2023
Filed with the SEC on Feb 13, 2024 and accepted by EDGAR at Feb 13, 2024, 16:25 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-10-01 to 2023-12-31 | $411.4k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2023-04-01 to 2023-12-31 | $866.7k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Research and development | 3 months2023-10-01 to 2023-12-31 | $4.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-04-01 to 2023-12-31 | $12.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-10-01 to 2023-12-31 | −$7.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-04-01 to 2023-12-31 | −$21.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-10-01 to 2023-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-04-01 to 2023-12-31 | $2.5k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-10-01 to 2023-12-31 | −$6.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-04-01 to 2023-12-31 | −$19.8m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2023-10-01 to 2023-12-31 | −$0.22 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-04-01 to 2023-12-31 | −$1.27 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 9 months2023-04-01 to 2023-12-31 | −$18.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-12-31 | $126.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $128.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $131.1m | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $4.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $7.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-12-31 | $123.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-24-003916. Last ingested by Listed: Oct 30, 2026, 17:32 ET. Listed shows no prices and gives no investment advice.